A placebo-controlled, double-blind clinical trial with two parallel groups depicted that for children (aged 6 months to 15 years) diagnosed with eosinophilic esophagitis, probiotics can be utilized as adjuvant therapy since it is associated with an improvement in poor appetite and intensity of chest pain, and decrease in the frequency of nausea.

Niloufar Amini et al. aimed to investigate the effectiveness of synbiotic on clinical symptoms improvement in 30 children suffering from eosinophilic esophagitis, an allergic inflammatory disorder of esophagus. Participants were randomly segregated into the intervention group and control group. Both the study groups were given the same treatment (proton pump inhibitor, elimination diet, and topical steroid).

A synbiotic was added to medication regimen of 15 participants (intervention or case group). On the other hand, the next 15 participants were given a placebo (control group). Using a checklist derived from a validated scoring tool, the frequency and severity of symptoms were determined in both the arms prior to and after eight weeks of therapy.

A considerable drop was noted in severity score of chest pain and poor appetite in case group receiving probiotics. In the case group, poor appetite and nausea were the only symptoms with a considerable  drop in the frequency score following intervention. Thus, the use of probiotics yields satisfactory outcomes in children having eosinophilic esophagitis.